---
name: InnoSer Laboratories
slug: innoserlaboratories
site: cro
website_domain: innoserlaboratories.com
summary: Preclinical CRO offering GLP and non-GLP toxicology, custom genetically modified mouse models, and disease models across oncology, neurology, immunology, metabolic, and cardiovascular research. Supports programs from target discovery through IND-enabling studies. Headquartered in Netherlands.
tagline: Your Discovery & Preclinical Partner
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: NL
tier2_domain_verified: false
updated_at: 2026-11-04T07:03:32.992Z
services_count: 13
modalities_count: 6
indications_count: 9
locations_count: 2
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# InnoSer Laboratories

Your Discovery & Preclinical Partner

Listed on cro.directory.

## Summary

Preclinical CRO offering GLP and non-GLP toxicology, custom genetically modified mouse models, and disease models across oncology, neurology, immunology, metabolic, and cardiovascular research. Supports programs from target discovery through IND-enabling studies. Headquartered in Netherlands.

## At a glance

- HQ country: NL

## Services

- GLP Toxicology
- In Vivo Efficacy Models
- Preclinical In Vivo Studies
- Specialized & Large-Animal Models
- Discovery Research
- Preclinical In Vitro Studies
- Biomarker Assays
- Pathology & Histology Services
- CNS Specialty Services
- Oncology Specialty Services
- Immunology & Inflammation Services
- Cardiovascular & Metabolic Specialty Services
- Translational Research

## Modalities

- Small Molecule
- Biologics (Other)
- Vaccine
- mRNA
- Cell Therapy
- Gene Therapy

## Indications

- Oncology
- Neurology
- Immunology
- Metabolic
- Cardiovascular
- Nephrology
- Rare Disease
- Gastroenterology
- Dermatology

## Locations

- Netherlands, Netherlands
- Belgium, Belgium

## Long description

## Overview

InnoSer is a contract research organization (CRO) based in the Netherlands and Belgium, supporting discovery and preclinical drug development. The company positions itself as a discovery and preclinical partner that works as an extension of client teams.

## Services

- GLP and GMP-compliant rodent and non-rodent toxicity studies for small molecules, biologicals, advanced therapy medicinal products (ATMPs), medical devices, chemicals, and food products
- Non-GLP toxicology and screening studies
- In vivo efficacy, dosing, safety, and pharmacokinetic studies
- In vitro assays, immunoassays, and biomarker analyses
- Pathology, rodent behavioral testing, and advanced imaging
- Genetically modified mouse model generation, colony breeding and management, genetic validation, and embryo and sperm cryostorage

## Therapeutic and model areas

- Oncology: syngeneic, cell line-derived, patient-derived, and humanized models; experience across vaccines, immuno-oncology, combination therapy, small molecules, biologics, and cell and gene therapy approaches
- Neurology: in vitro and in vivo models spanning neurodegenerative, neuromuscular, and rare neurodevelopmental conditions, including BBB drug delivery
- Immunology: delayed-type hypersensitivity, psoriasis, type 1 diabetes, inflammatory bowel disease, and EAE models; vaccine testing and mRNA/RNA therapy work
- Metabolic: mouse models of obesity, type 2 diabetes, and associated complications
- Cardiovascular: heart failure (HFrEF and HFpEF) and related cardiac models, including cardiac surgery
- Nephrology and rare disease: models such as ADPKD and other rare genetic conditions

## Development phases

InnoSer supports target validation, hit-to-lead, lead optimization, late-stage non-GLP preclinical studies, and IND-enabling studies.

Clients include more than 200 customers, according to the company website.

## Related companies

- [Inotiv](/companies/inotivco) (GLP Toxicology, In Vivo Efficacy Models) — [Compare](/compare/innoserlaboratories/inotivco)
- [Noble Life Sciences](/companies/noblelifesci) (GLP Toxicology, In Vivo Efficacy Models) — [Compare](/compare/innoserlaboratories/noblelifesci)
- [Crown Bioscience](/companies/crownbio) (In Vivo Efficacy Models, Preclinical In Vivo Studies) — [Compare](/compare/crownbio/innoserlaboratories)
- [Axcelead Drug Discovery Partners, Inc.](/companies/axcelead) (GLP Toxicology, In Vivo Efficacy Models) — [Compare](/compare/axcelead/innoserlaboratories)
- [Reaction Biology](/companies/reactionbiology) (GLP Toxicology, In Vivo Efficacy Models) — [Compare](/compare/innoserlaboratories/reactionbiology)
- [Esco Aster](/companies/escoaster) (GLP Toxicology, Preclinical In Vivo Studies) — [Compare](/compare/escoaster/innoserlaboratories)
- [Labcorp](/companies/labcorp) (GLP Toxicology, In Vivo Efficacy Models) — [Compare](/compare/innoserlaboratories/labcorp)
- [Cyagen Biosciences](/companies/apac-cyagen) (In Vivo Efficacy Models, Preclinical In Vivo Studies) — [Compare](/compare/apac-cyagen/innoserlaboratories)

_Profile last updated: 2026-11-04T07:03:32.992Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.